Résultats à plus de cinq ans du traitement de la rhizarthrose par la prothèse Rubis II. À propos de 118 implantations

Maes, C.; Dunaud, J.-L.; Moughabghab, M.; Benaissa, S.; Henry, L.; Gueriat, F.

doi:10.1016/j.main.2010.09.025

Cited by 25 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were eight dislocations (7.2%), which is within the range reported in the literature (Maes et al., 2010) or even lower (Regnard, 2013). In most cases, dislocations occurred during the first year after surgery, following minor trauma.…”

Section: Discussionsupporting

confidence: 77%

Results of 110 IVORY® prostheses for trapeziometacarpal osteoarthritis with a minimum follow-up of 10 years

Tchurukdichian¹,

Garcı́a-Dorado²,

Moris³

et al. 2020

J Hand Surg Eur Vol

View full text Add to dashboard Cite

The IVORY® prosthesis is a total trapeziometacarpal joint prosthesis used for the treatment of symptomatic trapeziometacarpal osteoarthritis. The aim of this prospective study was to evaluate its long-term outcomes with a minimum follow-up of 10 years. From 2004 to 2007, 110 trapeziometacarpal prostheses (95 patients) were implanted. The implant survival curve was constructed using the Kaplan–Meier method. Five patients were lost from follow-up and two died. Six prosthesis (5.5%) were removed after dislocation or fracture of the trapezium. The survival rate of the prosthesis was 95%. After 10 years, the mean visual analogue pain score was 0.24/10 and the key-pinch force was similar to the other hand. Dislocations occurred for eight implants (7.3%). No radiological loosening was noted. In conclusion, the long-term results with the IVORY® prosthesis are very satisfactory in terms of pain relief, function and survival. Level of evidence: II

show abstract

Section: Discussionsupporting

confidence: 77%

Results of 110 IVORY® prostheses for trapeziometacarpal osteoarthritis with a minimum follow-up of 10 years

Tchurukdichian¹,

Garcı́a-Dorado²,

Moris³

et al. 2020

J Hand Surg Eur Vol

View full text Add to dashboard Cite

show abstract

“…Dislocation rate is low in our series compared to other series such as ARPE prosthesis in the study by Jacoulet 28 (8%), Rubis II by Maes et al 29 (5%) and Maia prosthesis by Bricout and Rezzouk 24 (4.5%). A 2% to 5% dislocation rate was reported in a multicenter study of the Ivory prosthesis.…”

Section: Discussioncontrasting

confidence: 54%

Outcomes of Double-Mobility Prosthesis in Trapeziometacarpal Joint Arthritis With a Minimal 3 Years of Follow-Up: An Advantage for Implant Stability

Tchurukdichian

Gerenton

Moris

et al. 2019

Hand (New York, N,Y.)

View full text Add to dashboard Cite

Background: New generation of total trapeziometacarpal joint prosthesis using double mobility concept has been used for several years. The aim of this study was to evaluate the dislocation rate with this implant after a minimal 3 years of follow-up. Methods: From September 2013 to August 2015, 200 trapeziometacarpal prostheses were implanted in 179 patients. Clinico-radiological follow-up was performed with an average of 48.2 months (36-60 months). Survival rate and dislocation rate were analyzed. Loosening of the implants and other intercurrent events were noticed. Results: Visual analog scale, Quick-DASH, strengths and range of motion improved significantly. We report a survival rate of 97% with only 0.5% of dislocation of prosthesis at 48 months of follow-up. Intercurrent events rate were similar to the ones found in literature or other studies. Conclusions: After a minimal of 3 years of follow-up, prosthesis with double mobility seemed to bring better stability in implant for thumb prosthetic replacement.

show abstract

Endoprothetik am Daumensattelgelenk

2016

View full text Add to dashboard Cite

The role of joint replacement in the treatment of osteoarthritis of the thumb carpometacarpal joint is a subject of considerable controversy in the current literature. In German-speaking countries this technique is used much less frequently than resection procedures. Aseptic loosening of the prosthesis is believed to be the major cause of the high failure rates reported for cemented and uncemented types of implants. In this study the different implant designs were evaluated on the basis of the results reported in the international literature. There are only a few studies that cover relatively long follow-up periods and provide convincing results for thumb carpometacarpal joint prostheses in terms of implant survival and function. Aseptic loosening is reported to be the major cause with failure rates of 50 % or more. Although a Norwegian study reported high 5 and 10-year survival rates for various thumb carpometacarpal joint prostheses according to the Norwegian arthroplasty registry, it did not recommend the widespread use of thumb carpometacarpal joint replacement at the present time. In our opinion, joint replacement may be considered as a possible treatment option for advanced osteoarthritis of the thumb carpometacarpal joint but it should not always be recommended because long-term results are inconsistent and similar functional outcomes have been reported for alternative surgical techniques, such as resection arthroplasty.

show abstract

Résultats à plus de cinq ans du traitement de la rhizarthrose par la prothèse Rubis II. À propos de 118 implantations

Cited by 25 publications

References 21 publications

Results of 110 IVORY® prostheses for trapeziometacarpal osteoarthritis with a minimum follow-up of 10 years

Results of 110 IVORY® prostheses for trapeziometacarpal osteoarthritis with a minimum follow-up of 10 years

Outcomes of Double-Mobility Prosthesis in Trapeziometacarpal Joint Arthritis With a Minimal 3 Years of Follow-Up: An Advantage for Implant Stability

Endoprothetik am Daumensattelgelenk

Contact Info

Product

Resources

About